Arcadia Biosciences (RKDA)
(Delayed Data from NSDQ)
$2.76 USD
-0.09 (-2.99%)
Updated Sep 10, 2024 03:59 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Cash flow Statements
Fiscal Year End for Arcadia Biosciences, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -13.99 | -15.61 | -16.13 | -6.03 | -28.87 |
Depreciation/Amortization & Depletion | 0.98 | 1.77 | 7.27 | 1.67 | 0.72 |
Net Change from Assets/Liabilities | -3.51 | 0.12 | -4.26 | -12.37 | -0.59 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 1.22 | -0.25 | -12.74 | -13.49 | 11.55 |
Net Cash From Operating Activities | -15.29 | -13.98 | -25.87 | -30.22 | -17.20 |
Property & Equipment | 0.11 | 0.85 | -0.99 | -2.33 | -1.46 |
Acquisition/ Disposition of Subsidiaries | 0.57 | 0.57 | -4.25 | 2.65 | 0.00 |
Investments | -5.02 | 0.00 | 21.85 | 16.96 | -6.91 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -4.34 | 1.42 | 16.61 | 17.28 | -8.37 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 6.01 | 5.01 | 25.21 | 17.42 | 22.79 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | -2.15 | 3.07 | -0.01 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.50 | -0.49 | -1.16 | 0.06 | -0.80 |
Net Cash from Financing Activities | 5.51 | 4.52 | 21.90 | 20.56 | 21.99 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -14.13 | -8.04 | 12.64 | 7.63 | -3.58 |
Cash at Beginning of Period | 20.64 | 28.69 | 16.04 | 8.42 | 12.00 |
Cash at End of Period | 6.52 | 20.64 | 28.69 | 16.04 | 8.42 |
Diluted Net EPS | -11.30 | -25.65 | -27.60 | -18.80 | -181.20 |
Fiscal Year End for Arcadia Biosciences, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -1.36 | -2.42 | -13.99 | -11.13 | -8.57 |
Depreciation/Amortization & Depletion | 0.41 | 0.23 | 0.98 | 0.76 | 0.50 |
Net Change from Assets/Liabilities | -0.74 | -0.60 | -3.51 | -2.30 | -1.92 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | -3.98 | -0.42 | 1.22 | 1.52 | 1.73 |
Net Cash From Operating Activities | -5.67 | -3.21 | -15.29 | -11.15 | -8.26 |
Property & Equipment | 0.15 | 0.00 | 0.11 | 0.04 | 0.03 |
Acquisition/ Disposition of Subsidiaries | 2.00 | 0.00 | 0.57 | 0.57 | 0.57 |
Investments | 2.50 | 0.00 | -5.02 | -5.00 | -5.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 4.65 | 0.00 | -4.34 | -4.40 | -4.40 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.01 | 0.01 | 6.01 | 6.01 | 6.00 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | -0.50 | -0.50 | -0.50 |
Net Cash from Financing Activities | 0.01 | 0.01 | 5.51 | 5.51 | 5.51 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -1.01 | -3.20 | -14.13 | -10.03 | -7.16 |
Cash at Beginning of Period | 6.52 | 6.52 | 20.64 | 20.64 | 20.64 |
Cash at End of Period | 5.50 | 3.32 | 6.52 | 10.61 | 13.48 |
Diluted Net EPS | 0.78 | -1.78 | 0.84 | -1.89 | 0.61 |